Please enable JavaScript to continue using this application.

Compare $DNTH vs $TVTX | Chartloom

Compare

$DNTH vs $TVTX

Dianthus Therapeutics Inc · Travere Therapeutics Inc

DNTH

Dianthus Therapeutics Inc

TVTX

Travere Therapeutics Inc

Compare $DNTH vs $TVTX

Comparing Dianthus Therapeutics Inc and Travere Therapeutics Inc

DNTHDianthus Therapeutics Inc

TVTXTravere Therapeutics Inc

DNTHDianthus Therapeutics Inc

Market cap

$4.50B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3,009.80x

Rev growth (TTM)

-60.8%

YTD performance

107.6%

52W performance

137.0%

FCF yield

-3.5%

TVTXTravere Therapeutics Inc

Market cap

$4.85B

P/E (TTM)

—

Forward P/E (NTM)

30.06x

Forward P/S (NTM)

5.04x

Rev growth (TTM)

77.1%

YTD performance

31.9%

52W performance

99.0%

FCF yield

0.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

DNTH

TVTX

Detailed metrics comparison

DNTH

Dianthus Therapeutics Inc

TVTX

Travere Therapeutics Inc

Market Cap

DNTH$4.50B

TVTX$4.85B

Enterprise Value

DNTH$4.39B

TVTX$5.33B

Price

DNTH$82.37

TVTX$52.13

P/E Ratio

DNTHN/A

TVTXN/A

P/S Ratio

DNTH2,365.11x

TVTX8.20x

EV/Sales

DNTH2,307.05x

TVTX9.02x

EV/EBITDA

DNTH0.00x

TVTX216.50x

P/B Ratio

DNTH4.21x

TVTX218.84x

P/FCF Ratio

DNTHN/A

TVTX314.77x

EV/FCF

DNTH-28.21x

TVTX346.27x

PEG Ratio

DNTHN/A

TVTXN/A

Forward P/E (NTM)

DNTHN/A

TVTX30.06x

Forward P/S (NTM)

DNTH3,009.80x

TVTX5.04x

Revenue (TTM)

DNTH$2M

TVTX$591M

Revenue Growth (YoY)

DNTH-60.8%

TVTX77.1%

Forward Rev Growth

DNTH-5.4%

TVTX49.4%

Gross Margin (TTM)

DNTH0.0%

TVTX98.6%

Operating Margin (TTM)

DNTH0.0%

TVTX0.0%

EBITDA Margin (TTM)

DNTH-11434.9%

TVTX3.9%

Net Margin (TTM)

DNTH-10097.0%

TVTX-7.4%

FCF Margin (TTM)

DNTH-8178.0%

TVTX2.6%

Net Income (TTM)

DNTH$-192M

TVTX$-43M

FCF (TTM)

DNTH$-156M

TVTX$15M

EPS (TTM)

DNTH-$3.43

TVTX-$0.46

ROE (TTM)

DNTH-2253.0%

TVTX-5579.0%

ROA (TTM)

DNTH-2155.0%

TVTX-696.0%

ROIC (TTM)

DNTH-2253.0%

TVTX-940.0%

Cash

DNTH$111M

TVTX$118M

Debt

DNTH$0

TVTX$603M

Net Cash/Debt

DNTH$111M

TVTX$-485M

Current Ratio (TTM)

DNTH26.10x

TVTX4.05x

Quick Ratio (TTM)

DNTH25.80x

TVTX3.75x

Debt/Equity (TTM)

DNTH0.00x

TVTX24.58x

Debt/Assets (TTM)

DNTH0.0%

TVTX0.0%

Interest Coverage (TTM)

DNTHN/A

TVTXN/A

Net Debt/EBITDA (TTM)

DNTH0.00x

TVTX0.00x

Beta

DNTH1.99

TVTX1.08

52W Performance

DNTH137.0%

TVTX99.0%

YTD Performance

DNTH107.6%

TVTX31.9%

% from 52W High

DNTH-30.1%

TVTX-24.2%

% from 52W Low

DNTH155.6%

TVTX130.7%

Asset Turnover (TTM)

DNTH0.00x

TVTX0.95x

FCF Yield (TTM)

DNTH-3.5%

TVTX0.3%

Earnings Yield (TTM)

DNTH-4.3%

TVTX-0.9%

Dividend Yield (TTM)

DNTHN/A

TVTXN/A

Rule of 40

DNTH-8,238.8

TVTX79.7

EV/GP/RG

DNTHN/A

TVTX0.14

Ticker research

View DNTH research View TVTX research

Metric	DNTH Dianthus Therapeutics Inc	TVTX Travere Therapeutics Inc
Market & Valuation
Market Cap	$4.50B	$4.85B
Enterprise Value	$4.39B	$5.33B
Price	$82.37	$52.13
P/E Ratio	N/A	N/A
P/S Ratio	2,365.11x	8.20x
EV/Sales	2,307.05x	9.02x
EV/EBITDA	0.00x	216.50x
P/B Ratio	4.21x	218.84x
P/FCF Ratio	N/A	314.77x
EV/FCF	-28.21x	346.27x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	30.06x
Forward P/S (NTM)	3,009.80x	5.04x
Revenue & Growth
Revenue (TTM)	$2M	$591M
Revenue Growth (YoY)	-60.8%	77.1%
Forward Rev Growth	-5.4%	49.4%
Profitability
Gross Margin (TTM)	0.0%	98.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-11434.9%	3.9%
Net Margin (TTM)	-10097.0%	-7.4%
FCF Margin (TTM)	-8178.0%	2.6%
Net Income (TTM)	$-192M	$-43M
FCF (TTM)	$-156M	$15M
EPS (TTM)	-$3.43	-$0.46
ROE (TTM)	-2253.0%	-5579.0%
ROA (TTM)	-2155.0%	-696.0%
ROIC (TTM)	-2253.0%	-940.0%
Financial Health
Cash	$111M	$118M
Debt	$0	$603M
Net Cash/Debt	$111M	$-485M
Current Ratio (TTM)	26.10x	4.05x
Quick Ratio (TTM)	25.80x	3.75x
Debt/Equity (TTM)	0.00x	24.58x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.99	1.08
52W Performance	137.0%	99.0%
YTD Performance	107.6%	31.9%
% from 52W High	-30.1%	-24.2%
% from 52W Low	155.6%	130.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.95x
FCF Yield (TTM)	-3.5%	0.3%
Earnings Yield (TTM)	-4.3%	-0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-8,238.8	79.7
EV/GP/RG	N/A	0.14
Ticker research	View DNTH research	View TVTX research

Valuation

P/S Ratio

TVTX

8.20x

DNTH

2,365.11x

EV/FCF

DNTH

-28.21x

TVTX

346.27x

Growth & revenue

Revenue Growth TTM

TVTX

77.1%

DNTH

-60.8%

Forward Revenue Growth

TVTX

49.4%

DNTH

-5.4%

Profitability & performance

Gross Margin

TVTX

98.6%

DNTH

0.0%

ROE

DNTH

-2253.0%

TVTX

-5579.0%

FCF Yield %

TVTX

0.3%

DNTH

-3.5%

52-Week Performance

DNTH

137.0%

TVTX

99.0%

Detailed metrics comparison

DNTH

Dianthus Therapeutics Inc

TVTX

Travere Therapeutics Inc

Market Cap

DNTH$4.50B

TVTX$4.85B

Enterprise Value

DNTH$4.39B

TVTX$5.33B

Price

DNTH$82.37

TVTX$52.13

P/E Ratio

DNTHN/A

TVTXN/A

P/S Ratio

DNTH2,365.11x

TVTX8.20x

EV/Sales

DNTH2,307.05x

TVTX9.02x

EV/EBITDA

DNTH0.00x

TVTX216.50x

P/B Ratio

DNTH4.21x

TVTX218.84x

P/FCF Ratio

DNTHN/A

TVTX314.77x

EV/FCF

DNTH-28.21x

TVTX346.27x

PEG Ratio

DNTHN/A

TVTXN/A

Forward P/E (NTM)

DNTHN/A

TVTX30.06x

Forward P/S (NTM)

DNTH3,009.80x

TVTX5.04x

Revenue (TTM)

DNTH$2M

TVTX$591M

Revenue Growth (YoY)

DNTH-60.8%

TVTX77.1%

Forward Rev Growth

DNTH-5.4%

TVTX49.4%

Gross Margin (TTM)

DNTH0.0%

TVTX98.6%

Operating Margin (TTM)

DNTH0.0%

TVTX0.0%

EBITDA Margin (TTM)

DNTH-11434.9%

TVTX3.9%

Net Margin (TTM)

DNTH-10097.0%

TVTX-7.4%

FCF Margin (TTM)

DNTH-8178.0%

TVTX2.6%

Net Income (TTM)

DNTH$-192M

TVTX$-43M

FCF (TTM)

DNTH$-156M

TVTX$15M

EPS (TTM)

DNTH-$3.43

TVTX-$0.46

ROE (TTM)

DNTH-2253.0%

TVTX-5579.0%

ROA (TTM)

DNTH-2155.0%

TVTX-696.0%

ROIC (TTM)

DNTH-2253.0%

TVTX-940.0%

Cash

DNTH$111M

TVTX$118M

Debt

DNTH$0

TVTX$603M

Net Cash/Debt

DNTH$111M

TVTX$-485M

Current Ratio (TTM)

DNTH26.10x

TVTX4.05x

Quick Ratio (TTM)

DNTH25.80x

TVTX3.75x

Debt/Equity (TTM)

DNTH0.00x

TVTX24.58x

Debt/Assets (TTM)

DNTH0.0%

TVTX0.0%

Interest Coverage (TTM)

DNTHN/A

TVTXN/A

Net Debt/EBITDA (TTM)

DNTH0.00x

TVTX0.00x

Beta

DNTH1.99

TVTX1.08

52W Performance

DNTH137.0%

TVTX99.0%

YTD Performance

DNTH107.6%

TVTX31.9%

% from 52W High

DNTH-30.1%

TVTX-24.2%

% from 52W Low

DNTH155.6%

TVTX130.7%

Asset Turnover (TTM)

DNTH0.00x

TVTX0.95x

FCF Yield (TTM)

DNTH-3.5%

TVTX0.3%

Earnings Yield (TTM)

DNTH-4.3%

TVTX-0.9%

Dividend Yield (TTM)

DNTHN/A

TVTXN/A

Rule of 40

DNTH-8,238.8

TVTX79.7

EV/GP/RG

DNTHN/A

TVTX0.14

Ticker research

View DNTH research View TVTX research

Metric	DNTH Dianthus Therapeutics Inc	TVTX Travere Therapeutics Inc
Market & Valuation
Market Cap	$4.50B	$4.85B
Enterprise Value	$4.39B	$5.33B
Price	$82.37	$52.13
P/E Ratio	N/A	N/A
P/S Ratio	2,365.11x	8.20x
EV/Sales	2,307.05x	9.02x
EV/EBITDA	0.00x	216.50x
P/B Ratio	4.21x	218.84x
P/FCF Ratio	N/A	314.77x
EV/FCF	-28.21x	346.27x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	30.06x
Forward P/S (NTM)	3,009.80x	5.04x
Revenue & Growth
Revenue (TTM)	$2M	$591M
Revenue Growth (YoY)	-60.8%	77.1%
Forward Rev Growth	-5.4%	49.4%
Profitability
Gross Margin (TTM)	0.0%	98.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-11434.9%	3.9%
Net Margin (TTM)	-10097.0%	-7.4%
FCF Margin (TTM)	-8178.0%	2.6%
Net Income (TTM)	$-192M	$-43M
FCF (TTM)	$-156M	$15M
EPS (TTM)	-$3.43	-$0.46
ROE (TTM)	-2253.0%	-5579.0%
ROA (TTM)	-2155.0%	-696.0%
ROIC (TTM)	-2253.0%	-940.0%
Financial Health
Cash	$111M	$118M
Debt	$0	$603M
Net Cash/Debt	$111M	$-485M
Current Ratio (TTM)	26.10x	4.05x
Quick Ratio (TTM)	25.80x	3.75x
Debt/Equity (TTM)	0.00x	24.58x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.99	1.08
52W Performance	137.0%	99.0%
YTD Performance	107.6%	31.9%
% from 52W High	-30.1%	-24.2%
% from 52W Low	155.6%	130.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.95x
FCF Yield (TTM)	-3.5%	0.3%
Earnings Yield (TTM)	-4.3%	-0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-8,238.8	79.7
EV/GP/RG	N/A	0.14
Ticker research	View DNTH research	View TVTX research